The record
Written from the 1 report below. Nothing here is unsourced.
- India's drug regulator has approved Qdenga, a tetravalent dengue vaccine made by Japan's Takeda, for use in people aged four to 60 regardless of prior dengue exposure.
- It is given as two injections three months apart and is expected to be available in the first half of 2027, initially through private healthcare facilities.
- The approval matters because India carries nearly one-third of the global dengue burden, with cases rising sharply in the past two decades.
- However, the vaccine is not a complete fix, as trial efficacy varied by dengue serotype, with clearer protection against DENV-1 and DENV-2 in people never previously infected.
What to watch next
- Availability of Qdenga through private healthcare facilities, expected in the first half of 2027
- Expansion of manufacturing through Takeda's partnership with Hyderabad-based Biological E
- How efficacy holds against DENV-3 and DENV-4 in dengue-naive recipients
Coverage1
1 report
English national1
All filed from India
Named India · Brazil · Japan · Thailand · Philippines · Sri Lanka · Colombia · Panama · Dominican Republic · Nicaragua · European Union
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.